Acrivon Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Net Income	-60.39	-31.17	-16.24	-5.31
Depreciation & Amortization	1.31	1.1	0.83	0.01
Share-Based Compensation	11.62	2.19	0.5	0
Other Operating Activities	4.82	-2.23	0.93	2.49
Operating Cash Flow	-42.64	-30.12	-13.98	-2.8
Capital Expenditures	-1.29	-2.17	-0.24	-0.02
Change in Investments	52.01	-139.51	0	0
Investing Cash Flow	50.72	-141.68	-0.24	-0.02
Share Issuance / Repurchase	0.78	104.48	0	0
Debt Issued / Paid	0	0	0	0.06
Other Financing Activities	-2.33	-2.77	112.22	2.83
Financing Cash Flow	-1.55	101.71	112.22	2.89
Net Cash Flow	6.52	-70.08	98	0.07
Free Cash Flow	-43.93	-32.28	-14.22	-2.82
Free Cash Flow Per Share	-1.99	-7.83	-8.16	-1.97

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).